Form D · Pharmaceuticals
KEMPHARM, INC
Celebration, FL · CIK 0001434647
Offering snapshot reported Jun 22, 2021 · SEC filing
- Reported sold
- $39.1M Offering amount: $39.1M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 18, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 22, 2021 | Initial | $39,098,530 | No comparison | 12 | SEC filing |
| Feb 4, 2021 | Initial | $44,025,381 | No comparison | 15 | SEC filing |
| Jan 13, 2021 | Initial | $31,476,984 | No comparison | 4 | SEC filing |
| Jan 13, 2020 | Initial | $3,037,354 | No comparison | 1 | SEC filing |
| Dec 23, 2019 | Initial | $71,418,011 | No comparison | 3 | SEC filing |
| Nov 2, 2018 | Initial | $1,150,000 | No comparison | 1 | SEC filing |
| Mar 4, 2015 | Initial | $4,000,000 | No comparison | 1 | SEC filing |
| May 30, 2013 | Initial | $762,000 | No comparison | 10 | SEC filing |
| Jun 30, 2011 | Amendment | $6,852,006 | No comparison | 216 | SEC filing |
| Jul 15, 2010 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Aug 27, 2009 | Amendment | $3,489,385 | $3,479,385vs May 1, 2009 | 134 | SEC filing |
| May 1, 2009 | Initial | $10,000 | No comparison | Not reported | SEC filing |
| May 6, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $2.35M
- Finders' fees
- $0
- Form D file number
- 021-403827
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Roth Capital Partners, LLC | 15407 |
Source: Form D, filed Jun 22, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Beardsley | Director |
| Robert Beardsley, Ph.D. | Director |
| Adam Claypool | Director |
| R. La Duane Clifton | Executive |
| Todd Doorenbos | Director |
| Sven Guenther | Executive |
| Kathleen H. Holt | Executive |
| Todd Johnson | Director |
| Gordon K. Johnson | Executive |
| Robert Karr | Director, Executive |
| Karlton Kleis | Director |
| Christopher Lauderback | Executive |
| Jonathan S. Leff | Director |
| Travis C. Mickle | Director, Executive, Promoter |
| Christal M.M. Mickle | Director, Executive |
| Richard W. Pascoe | Director |
| Matt Plooster | Director |
| Matthew R. Plooster | Director |
| Joseph B. Saluri | Director |
| Timothy J. Sangiovanni | Executive |
| Danny L. Thompson | Director |
| Dan Thompson | Director |
| David S. Tierney | Director |
| Tracy M. Woody | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1180 Celebration Boulevard, Suite 103
Celebration, FL, 34747
Celebration, FL, 34747